ELIQUIS (apixaban) dosing for patients with DVT / PE
ELIQUIS for the treatment of DVT / PE and prevention of recurrent DVT / PE
The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding.1
Duration of overall treatment should be individualised after careful assessment of the treatment benefit against the risk for bleeding.1
* As per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation)
No dose adjustment for DVT / PE patients, based on age, weight or those with mild-to-moderate renal impairment.1 ELIQUIS should be used with caution in patients with severe renal impairment (CrCl 15–29 ml/min) for the treatment of DVT / PE and prevention of recurrent DVT / PE. ELIQUIS is not recommended in patients with CrCl <15 ml/min, or in patients undergoing dialysis.1
No initial injections or bridging with LMWH required1
ELIQUIS can be taken with or without food1
Missed dose: if a dose is missed, the patient should take ELIQUIS immediately and then continue with twice-daily intake as before1
Liver function testing should be performed prior to initiating ELIQUIS1
Please click here to access the ELIQUIS Patient Information Leaflet.
Reference
- ELIQUIS® (apixaban) Summary of Product Characteristics.